Human Pluripotent Stem Cells Go Diabetic: A Glimpse on Monogenic Variants

Front Endocrinol (Lausanne). 2021 May 17:12:648284. doi: 10.3389/fendo.2021.648284. eCollection 2021.

Abstract

Diabetes, as one of the major diseases in industrial countries, affects over 350 million people worldwide. Type 1 (T1D) and type 2 diabetes (T2D) are the most common forms with both types having invariable genetic influence. It is accepted that a subset of all diabetes patients, generally estimated to account for 1-2% of all diabetic cases, is attributed to mutations in single genes. As only a subset of these genes has been identified and fully characterized, there is a dramatic need to understand the pathophysiological impact of genetic determinants on β-cell function and pancreatic development but also on cell replacement therapies. Pluripotent stem cells differentiated along the pancreatic lineage provide a valuable research platform to study such genes. This review summarizes current perspectives in applying this platform to study monogenic diabetes variants.

Keywords: Maturity Onset of Diabetes in the Young; diabetes; monogenic variants; pluripotent stem cells; type 1 diabetes; type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • CRISPR-Cas Systems
  • Cell Differentiation
  • Cell Lineage
  • Diabetes Mellitus, Type 1 / genetics*
  • Diabetes Mellitus, Type 1 / metabolism*
  • Diabetes Mellitus, Type 2 / genetics*
  • Diabetes Mellitus, Type 2 / metabolism*
  • Embryonic Stem Cells / cytology
  • Epigenesis, Genetic
  • Gene Editing
  • Genetic Variation
  • Heterozygote
  • Humans
  • Insulin / metabolism
  • Insulin-Secreting Cells / metabolism
  • Mice
  • Mice, Knockout
  • Mutation*
  • Pancreas / embryology
  • Pancreas / pathology
  • Phenotype
  • Pluripotent Stem Cells / cytology*
  • Regeneration

Substances

  • Insulin